Occult primary: Clinical practice guidelines in oncology

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue 10, 2008, Pages 1026-1060

  Ettinger, David S ^a   Agulnik, Mark ^b   Cristea, Mihaela ^c   Eaton, Keith ^d   Fidias, Panagiotis M ^e   Gockerman, Jon P ^f   Hameed, Omar ^g   Handorf, Charles ^h   Harris, Elizabeth I ⁱ   Jacobs, Charlotte D ^j   Javle, Milind ^k   Khushalani, Nikhil I ^l   Kvols, Larry ^m   Lenzi, Renato ^k   Lewis, Nancy L ⁿ   Rashid, Asif ^k   Saltz, Leonard ^o   Shulman, Lawrence N ^p   Zager, Jonathan S ^m   Zhen, Weining ^q  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d SEATTLE CANCER CARE ALLIANCE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^f DUKE CANCER INSTITUTE   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

ⁱ VANDERBILT INGRAM CANCER CENTER   (United States)

^j STANFORD CANCER INSTITUTE   (United States)

^k UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^l ROSWELL PARK CANCER INSTITUTE   (United States)

^m H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁿ FOX CHASE CANCER CENTER   (United States)

^o MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^p Dana Farber Brigham and Women's Cancer Center   (United States)

^q NEBRASKA MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CALCIUM; CARBOPLATIN; CISPLATIN; CREATININE; DOCETAXEL; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; PACLITAXEL; PLATINUM DERIVATIVE; TEMOZOLOMIDE; THALIDOMIDE;

ADENOCARCINOMA; ARTICLE; CALCIUM BLOOD LEVEL; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME ABERRATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER FUNCTION TEST; METASTASIS; MONOTHERAPY; NEUROENDOCRINE TUMOR; OCCULT CANCER; OVERALL SURVIVAL; PARACENTESIS; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; PROGNOSIS; PROTON THERAPY; RADIOIMMUNOTHERAPY; SQUAMOUS CELL CARCINOMA; THORACOCENTESIS; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINALYSIS; CANCER OF UNKNOWN PRIMARY SITE; REVIEW;

CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS, UNKNOWN PRIMARY; PRACTICE GUIDELINES AS TOPIC;

EID: 57449088610     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2008.0078     Document Type: Article

References (72)

1. Greco FA, Hainsworth JD. Cancer of unknown primary site. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001:2537-2560.
2. Greco FA. Tumors of unknown origin. CA Cancer J Clin 1992;42: 96-115.
3. Hillen HF. Unknown primary tumours. Postgrad Med J 2000;76: 690-693.
4. Bugat R, Bataillard A, Lesimple T, et al. Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer 2003; 89(Suppl 1);S59-66.
5. Blaszyk H, Hartmann A, Bjornsson J. Cancer of unknown primary: clinicopathologic correlations. APMIS 2003;111:1089-1094.
6. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
7. van de Wouw AJ, Jansen RL, Speel EJ, et al. The unknown biology of the unknown primary tumor: a literature review. Ann Oncology 2003;14:191-196.
8. Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol 2005;54:243-250.
9. Briasoulis E, Tsokos M, Fountzilas G, et al. Bc12 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study. Anticancer Res 1998;18:1907-1914.
10. Pavlidis N, Briasoulis E, Hainsworth J, et al. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003;39:1990-2005.
11. Chorost MI, Lee MC, Yeoh CB, et al. Unknown primary. J Surg Oncol 2004;87:191-203.
12. Hainsworth JD. In: Pazdur R, Hoskins WJ, Coia LR, Wagman LD, eds. Cancer Management: A Multidisciplinary Approach. 9th ed. Lawrence, Kansas: CMP Healthcare Media; 2005:665-673.
13. Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N Engl J Med 1993;329:257-263.
14. van de Wouw AJ, Jansen RL, Griffioen AW, Hillen HF. Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. Anticancer Res 2004;24:297-301.
15. Jereczek-Gossa BA, Jassem J, Oreochia R. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary. Cancer Treat Rev 2004;30:153-164.
16. Lenzi R, Hess KR, Abbruzzese MC, et al. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients wirh unknown primary carcinoma. J Clin Oncol 1997;15:2056-2066.
17. Abbruzzese JL, Abbruzzese MC, Hess KR, et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994;12:1272-1280.
18. Pavlidis N. Cancer of unknown primary: biological and clinical characteristics. Ann Oncol 2003;14(Suppl 3):11-18.
19. Valentine J, Rosenthal S, Arseneau JC. Combination chemotherapy for adenocarcinoma of unknown primary origin. Cancer Clin Trials 1979;2:265-268.
20. Woods RL, Fox RM, Tattersall MH, et al. Metastatic adenocarcinomas of unknown primary: a randomized study of two combination-chemotherapy regimens. N Engl J Med 1980;303:87-89.
21. Schildt RA, Kennedy PS, Chen TT, et al. Management of patients with metastatic adenocarcinoma of unknown origin: a Southwest Oncology Group study. Cancer Treat Rep 1983;67:77-79.
22. Goldberg RM, Smith FP, Ueno W, et al. 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary. J Clin Oncol 1986;4:395-399.
23. Pasterz R, Savaraj N, Burgess M. Prognostic factors in metastatic carcinoma of unknown primary. J Clin Oncol 1986;4:1652-1657.
24. Eagan RT, Therneau TM, Rubin J, et al. Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site: a randomized trial. Am J Clin Oncol 1987;10:82-85.
25. Milliken ST, Tattersall MH, Woods RL, et al. Metastatic adenocarcinoma of unknown primary site: a randomized study of two combination chemotherapy regimens. Eur J Cancer Clin Oncol 1987;23: 1645-1648.
26. van der Gaast A, Verweij J, Planting AS, et al. 5-fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary. Eur J Cancer 1988;24:765-768.
27. Alberta AS, Falkson G, Falkson HC, et al. Treatment and prognosis of metastatic carcinoma of unknown primary: analysis of 100 patients. Med Pediatr Oncol 1989;17:188-192.
28. Bécouarn Y, Brunet R, Barbé-Gaston C. Fluorouracil, doxorubicin, cisplatin and altretamine in the treatment of metastatic carcinoma of unknown primary. Eur J Cancer 1989;25:861-865.
29. Schneider BJ, El-Rayes B, Muler JH, et al. Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site. Cancer 2007;110:770-775.
30. Greco FA, Burris HA III, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol 2002;20:1651-1666.
31. Hainsworth JD, Spigel DR, Farley C, et al. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol 2007;25:1747-1752.
32. Greco FA, Burris HA III, Spigel DR, et al. Paclitaxel/carboplatin (PC) plus bevacizumab/erlotinib as first-line treatment for patients (pts) with carcinoma of unknown primary (CUP) site [abstract]. J Clin Oncol 2008;26:Abstract 4607.
33. Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 1992;10:912-922.
34. van der Gaast A, Verweij J, Henzen-Logmans SC, et al. Carcinoma of unknown primary: identification of a treatable subset? Ann Oncol 1990;1:119-122.
35. Hainsworth JD, Erland JB, Kalman LA, et al. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin and extended-schedule etoposide. J Clin Oncol 1997;15:2385-2393.
36. Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 2000;18: 3101-3107.
37. Greco F, Burris, H, Erland J, et al. Carcinoma of unknown primary site: long term follow-up after treatment with paclitaxel, carboplatin, and etoposide. Cancer 2000;89:2655-2660.
38. Greco FA, Rodriguez GI, Shaffer DW, et al. Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial. Oncologist 2004;9:644-652.
39. Greco F, Erland J, Morrissey H, et al. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 2000;11:211-215.
40. Culine S, Lortholary A, Voigt J, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 2003;21:3479-3482.
41. Pouessel D, Culine S, Becht C, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary Site. Cancer 2004;100:1257-1261.
42. Hitt R, López-Pousa A, Martínez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005;23: 8636-8645.
43. Calais G, Pointreau Y, Alfonsi M, et al. Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01 [abstract]. J Clin Oncol 2006;24(18 Suppl):Abstract 5506.
44. Hainsworth J, Spigel D, Litchy S, et al. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network study. J Clin Oncol 2006;24:3548-3554.
45. Fjällskog ML, Granberg, D, Welin S, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001;92:1101-1107.
46. Okamoto H, Watanabe K, Kunikane H, et al. Randomised phase III trial of carboplatin plus etoposide vs. split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 2007;97:162-169.
47. Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986-2991.
48. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401-406.
49. Bucci MK, Bevan A, Roach M III. Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond. CA Cancer J Clin 2005;55:117-134.
50. Demir H, Berk F, Raderer M, et al. The role of nuclear medicine in the diagnosis of cancer of unknown origin. Q J Nucl Med Mol Imaging 2004;48:164-173.
51. Kole AC, Nieweg OE, Pruim J, et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998;82: 1160-1166.
52. Delgado-Bolton RC, Fernandez-Perez C, Gonzalez-Mate A, Carreras JL. Meta-analysis of the performance of F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med 2003;44:1301-1314.
53. Seve P, Billotey C, Broussolle C, et al. The role of 2-deoxy-2-[F-18]fluoro-d-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 2007;109:292-299.
54. Townsend DW, Carney JP, Yap JT, Hall NC. PET-CT today and tomorrow. J Nucl Med 2004;45:4S-14S.
55. Gutzeit A, Antoch G, Kuhl H, et al. Unknown primary tumors: detection with dual-modality PET-CT - initial experience. Radiology 2005;234:227-234.
56. Pelosi E, Pennone M, Deandreis D, et al. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Q J Nucl Med Mol Imaging 2006;50:15-22.
57. Nanni C, Rubello D, Castellucci P, et al. Role of 18F-FDG PET-CT imaging for the detection of an unknown primary tumour: preliminary results in 21 patients. Eur J Nucl Med Mol Imaging 2005;32: 589-592.
58. Buchanan CL, Morris EA, Dorn PL, et al. Utility of breast magnetic resonance imaging in patients with occult primary breast cancer. Ann Surg Oncol 2005;12:1045-1053.
59. Bleicher RJ, Morrow M. MRI and breast cancer: role in detection, diagnosis, and staging. Oncology (Williston Park) 2007;21:1521-1528.
60. Bhatia SK, Saclarides TJ, Witt TR, et al. Hormone receptor studies in axillary metastases from occult breast cancer. Cancer 1987;59: 1170-1172.
61. Varadhachary GR, Abbruzzese J, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer 2004;100:1776-1785.
62. Hainsworth JD, Johnson DH, Greco FA. Poorly differentiated neuroendocrine carcinoma of unknown primary site: a newly recognized clinicopathologic entity. Ann Intern Med 1988;109:364-371.
63. Moertel CG, Kvols LK, O'Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991-68:227-233.
64. Dabbs DJ. Diagnostic Immunohistochemistry, 1st ed. Philadelphia: Churchill Livingstone; 2002.
65. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002;40:403-439.
66. Bahrami A, Truong LD, Ro JY. Undifferentiated tumor: true identity by immunohistochemistry. Arch Pathol Lab Med 2008;132:326-348.
67. Muggia FM, Baranda J. Management of peritoneal carcinomatosis of unknown primary tumor site. Semin Oncol 1993;20:268-272.
68. Strnad CM, Grosh WW, Baxter J, et al. Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma. Ann Intern Med 1989;111:213-217.
69. Cuarischi A, Keane TJ, Elhakim T. Metastatic inguinal nodes from an unknown primary neoplasm: a review of 56 cases. Cancer 1987;59:572-577.
70. Abbruzzese JL, Abbruzzese MC, Lenzi R, et al. Analysis of diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 1995;13:2094-2103.
71. van der Hiel B, Stokkel MP, Chiti A, et al. Effective treatment of bone metastases from a neuroendocrine tumour of the pancreas with high activities of indium-111-pentetreotide. Eur J Endocrinol 2003;149: 479-483.
72. Hawksworth J, Geisinger K, Zagoria R, et al. Surgical and ablative treatment for metastatic adenocarcinoma to the liver from unknown primary tumor. Am Surg 2004;70:512-517.